Blood Market Size, Share & Trends Analysis Report By Product (Whole Blood Collection and Processing, Source Plasma Collection, Blood Typing Products, Blood Screening Products), By End-User (Blood and Blood Component Bank, Diagnostic Laboratories, Ambulatory Surgical Centers, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Blood Market Size

The global blood market size was valued at USD 8.94 billion in 2024 and is projected to grow from USD 9.38 billion in 2025 to reach USD 14.03 billion by 2033, exhibiting a CAGR of 5.16% during the forecast period (2025-2033).

Blood is a specialized and essential body fluid that comprises four major components, i.e., plasma, platelets, RBCs, and WBCs. Each component plays a vital role in various diagnostics and therapeutic applications, particularly for patients suffering from blood-related disorders such as cardiovascular diseases, cancer, and hematological conditions. This wide-ranging applicability fuels the growth of the global market.

Furthermore, the rising prevalence of trauma, accidents, and surgeries necessitates an increased demand for blood products. The surge in surgical procedures, combined with the growing incidences of trauma and chronic diseases, significantly contributes to the expanding market. Advancements in medical technologies, such as processing automation and storage systems, are also improving the safety and efficiency of RBC transfusions.

Blood Market Trends

Automation in blood processing

Automation in the processing of whole blood significantly enhances operational efficiency by smoothening every step from collection to distribution. Automated systems also reduce human interventions, resulting in the minimization of errors and inconsistencies that humans can cause. These systems also ensure high consistency and precision in blood processing by automating tasks such as separation, filtration, and storage.

• For instance, in October 2024, Sanquin adopted Terumo BCT’s Revos Automated Blood Processing System to boost efficiency in processing and enhance the production of critical products.

Personalized blood products

The trend towards personalized blood products in the market reflects a growing patient need according to individual needs, such as resembling particular cell types and immune profiles to gain therapeutic outcomes on a long-term basis.

• For instance, in November 2024, researchers from the University of Nottingham developed a new bio-cooperative material from RBC, which has proven effective in bone repair, showing the path for personalized regenerative products of blood potential in treating disease and injuries.

As patients increasingly seek long-term solutions, personalized RBC products provide more precise and effective treatments. This indicates a broader shift towards precision medicine, aiming for better health outcomes based on individualized care.

Blood Market Growth Factors

Rising prevalence of blood-related disorders

The growing prevalence of blood-related disorders, such as cancer, is significantly driving the demand for RBC and RBC components. With an increasing number of individuals diagnosed with conditions requiring transfusions, including cancer, trauma, and surgical procedures, the need for blood products continues to rise. The demand is particularly strong for RBCs, plasma, and platelets, which are crucial in managing such conditions.

• For instance, a report from Globocan in October 2024 revealed that more than 70,000 patients in India alone died from blood cancer, highlighting the need for improved product availability.

Technological innovations in medical treatment

Technological advancements are accelerating the growth of the blood market by improving the accuracy and efficiency of RBC transfusions and related treatments. Innovations, such as mobile blood testing technology, are enhancing traceability and reducing human error during vital procedures.

• For example, in November 2024, HemaChrome partnered with Global Health Labs to advance mobile health technology for more efficient blood hemoglobin testing, making it easier to manage blood-related conditions on a broader scale.

These improvements not only increase patient trust but also encourage further investment in the sector.

Market Restraining Factors

High cost involved in blood collection and processing

The high cost of blood collection, processing, and screening is a significant barrier to the widespread availability and utilization of RBC products, particularly in healthcare facilities with limited budgets. This high cost restricts the ability to implement advanced technologies for blood collection and testing, impacting the overall efficiency of blood banks and hospitals. Moreover, the cost of RBC screening for infections further complicates the process, adding financial strain to both healthcare providers and patients.

Blood Market Opportunities

Growing need for remote blood transfusion procedures

There is a growing opportunity to address the demand for blood transfusions in rural areas, where access to medical facilities and hematic fluid transfusion services is often limited. With more people migrating to urban centers, rural regions face an increasing need for efficient hematic fluid delivery solutions. Innovative approaches such as drone-based blood delivery, intraoperative autotransfusions, and mobile blood banks could significantly improve access to hematic fluid in these underserved areas.

• For example, in August 2024, the Associations for the Advancement of Blood and Biotherapies announced efforts to eradicate "blood deserts" through technology, highlighting the potential of these innovations to meet the growing demand for hematic fluid in remote areas.

Regional Insights

North America: Dominant region with 35.67% market share

North America holds a dominant position in the global market, driven by advanced technologies in blood processing, screening, and blood-related devices that enhance clinical development for treating chronic illnesses. The region is at the forefront of innovations aimed at improving the efficiency and safety of blood transfusions and therapies derived from blood components. These innovations accelerate the clinical development of therapies used in managing conditions like cancer, anemia, and trauma recovery.

Moreover, ongoing research and development in creating new blood-based treatments for various diseases contribute to the region's strong market share. As North American healthcare institutions continue to invest in cutting-edge technologies, such as automated hematic fluid screening and artificial blood substitutes, the region is expected to maintain its leadership.

Asia-Pacific: Fastest growing region with highest market CAGR

The Asia-Pacific region is witnessing the fastest growth in the global market, driven by a rising incidence of chronic illnesses like cancer, hemophilia, and immune deficiencies. This surge in demand for hematic fluid and derived products is shaping the future of the market in the region.

• For instance, in India, approximately 1.3 million people are diagnosed with cancer annually, and nearly 850,000 people died from the disease in 2020, as reported by the Indian Cancer Society.

This increasing cancer burden significantly boosts the need for hematic fluid components such as platelets and plasma for treatment. As healthcare infrastructure improves across Asia-Pacific countries, the demand for blood transfusions and related treatments continues to grow, spurring the development of blood banks, donation camps, and modern blood processing techniques.

Country Insights

The market is experiencing dynamic growth and diversification across the globe, with each country contributing uniquely to the advancement of this transformative field. Below are a few countries that illustrate the diverse contributions and advancements in the blood industry.

• U.S. - The U.S. leads the global market, driven by a high demand for blood and blood-related components such as platelets, RBCs, and plasma. According to the American Red Cross, blood or platelets are needed every 2 seconds, and nearly 29,000 units of RBCs, along with 6,500 units of plasma and 5,000 units of platelets, are required each day.
• Canada - Canada’s blood market growth is fueled by a rising number of patients suffering from chronic conditions, particularly cancer. The Canadian Cancer Society projects that around 45% of Canadian men and 43% of Canadian women will develop cancer in their lifetime. With an aging population, cancer cases continue to rise, increasing the demand for RBC products.
• Germany - Germany’s well-established healthcare system, coupled with rigorous safety standards for RBC products, contributes to a strong demand for RBCs and related components. Blood products in Germany must undergo evaluation at the Paul-Ehrlich-Institut, ensuring their efficacy, quality, and safety before reaching the market.
• India - India is witnessing significant growth in the market for blood, driven by a large demand for RBC units. The country requires approximately 14.6 million RBC units annually, with transfusions occurring every 2 seconds. Government initiatives like “Raktdaan Amrit Mahotsav” are raising awareness and promoting RBC donations through a series of national campaigns.
• China- China's blood industry is expanding rapidly, fueled by advancements in hematology research. In 2023 alone, Chinese researchers published 3,505 scientific papers on hematology, reflecting the country's commitment to medical research and its growing community of hematology experts, which is driving the expansion of the market.
• Japan- Japan’s market is evolving due to various initiatives, including efforts by student volunteers to encourage young adults to donate blood. Social media is also being used to spread the message. However, Japan faces a potential shortage of RBC donors due to a decline in young donors, highlighting the importance of these initiatives.
• South Korea - South Korea’s market is experiencing growth, driven by the increasing number of patients with severe health conditions and the aging population. Hospitals require a constant supply of whole RBCs and apheresis units to treat elderly patients with critical conditions.
• Singapore - Singapore is witnessing growth in its market, with a high demand for RBC products. According to the Health Sciences Authority, the country needs 14 units of RBC per hour, totaling approximately 118,750 units per year by 2024.

Segmentation Analysis

The global blood market is segmented into product and end-user

By Product

Whole blood collection and processing segment dominates the market with the highest market revenue

The whole blood collection and processing segment leads the market due to the widespread applications of whole blood in treating chronic conditions like hematological disorders, kidney disease, and trauma-related blood loss. Whole blood is also essential for transfusions, especially in cancer treatment, surgical procedures, and emergencies.

• For instance, in June 2022, the WHO reported that 118.5 million units of donated hematic fluid are collected worldwide. However, there remains a significant need for more donations to meet global transfusion demands.

By End User

Blood and blood component bank segment dominates the market with the highest market revenue

The blood and blood component bank segment holds the largest blood market share by end users, driven by the critical role these facilities play in ensuring the availability and storage of blood in optimal conditions for future use. Blood banks not only store whole blood but also plasma, platelets, and other components, which are essential for a variety of medical treatments, including surgeries, cancer care, and trauma management. These facilities also facilitate key processes such as hematic fluid collection, screening, and processing, ensuring the safety and efficacy of hematic fluid products.

Company Market Share

Key market players in the blood market are strategically investing in product innovation and expanding their product portfolios to meet growing consumer demand for convenience, safety, and sustainability. Companies are focusing on developing therapies derived from RBC and plasma to address the solution for life-threatening medical conditions.

Kedrion Biopharma: An emerging player in the market

Kedrion Biopharma is an emerging player in the market for blood , gaining attention for its innovative offerings of rare disease medicines and plasma derivatives. The company offers uniquely developed plasma-derived therapies used to treat and prevent serious and rare conditions such as neurological disorders, coagulation, and primary and secondary immunodeficiencies.

Recent developments at Kedrion Biopharma include:

• In November 2024, Kedrion Biopharma’s manufacturing facility in Bolognana, Italy, received FDA approval to produce RYPLAZIM, a plasma-derived treatment for plasminogen deficiency type 1 (PLGD-1), offering new hope for managing such rare chronic condition.

Recent Developments

• October 2024 - Terumo Blood and Cell Technologies (Terumo BCT) introduced the Reveos Automated Blood Processing System in the U.S. This innovative system is designed to help blood centers meet the increasing demand for blood and platelets while simultaneously improving staff efficiency and processing capabilities, enhancing overall operational effectiveness in blood collection facilities.
• September 2024 - Biotest launched its 13th plasma collection center in Karlsruhe, Germany, situated at Europaplatz, Kaiserstrasse. The modern facility is capable of collecting 146-148 plasma donations five days a week, from Monday to Friday. This expansion enhances Biotest's ability to meet the growing demand for plasma products and improve supply chain reliability.

Analyst Opinion

As per our analyst, the blood market is set for significant growth, fueled by rising awareness around blood donation drives and the increasing prevalence of chronic diseases that require timely blood transfusions. Innovations such as automation in blood processing and the development of personalized blood products are expected to play a key role in improving blood safety and therapeutic outcomes.

Moreover, the growing frequency of trauma cases and surgical procedures is driving the demand for RBC and its components, further propelling market expansion. These factors combined suggest a promising outlook for the blood market in the coming years.